Boston, June 17

Welcome to hubXchange’s Boston Antibody Therapeutics Xchange 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US


  • Computational approach for target selection
  • How to ensure target specificity to avoid unintended interactions with other proteins and molecule
  • Challenging membrane antibody targets: Brainstorming in-parallel in vivo and in vitro methodologies to identify rare and precious functional Ab candidates
  • Next Gen Antibodies Addressing the Road Blocks for 1st Gens
  • Fc engineering for improved antibody druggability
  • Considerations for CAR-T/ CAR-NK cell binder format designs during screening and selections
  • Developing bispecifics targeting novel targets
  • Immuno-oncology tumour-specific approach through multispecific therapeutics
  • Novel delivery modes for biologics – beyond parenteral administration and beyond classical protein administration
  • Using AI, AlphaFold and ML methods for therapeutics discovery and optimization

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Titles and Bullets
8:00 – 8:30
8:30 – 9:00

Opening Address & Keynote Presentation by Ablexis and AlivaMab Discovery Services

9:05 – 10:05
Target selection to avoid off-target effect and cross-reactivity with healthy tissues
  • How to identify and select a solid tumor target?
  • How to avoid off-target effects and cross-reactivity with healthy tissues ?
  • How to select targets for Ab discovery with potential for ADC development ? 
  • Is there a preferred Ab format to minimize development risk?

Zhinan has more than 25 year’s industrial mAb and CART cell therapy RDexperience.

Zhinan Xia
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:45 – 11:15
1-2-1 Meetings/Networking Break
11:15 – 11:25
Morning refreshments
12:30 – 13:30
Networking Lunch
13:30 – 14:00

Spotlight Presentation by WuXi

14:05– 14:35
1-2-1 Meetings/Networking Break
14:40 – 15:10
1-2-1 Meetings/Networking Break
15:15 – 15:45
Spotlight Presentation by Avantgen
Engineering Unique Properties in Next-Gen Antibody Therapies
15:50 – 16:20

1-2-1 Meetings/Networking Break

16:20 – 16:30

Afternoon refreshments

16:30 – 17:00

Poster Presentation:
Lead Identification & Optimization topic: Pioneer Platform: A Novel Biotherapeutic Antibody Discovery Platform

(Topic & Track TBC)

17:05 – 18:05

Strategies for target selection

  • What does a protein engineer bring to the table when selecting therapeutic targets?
  • What are new or emerging bioinformatic databases for target ranking?
  • Tips on Tabs/ mining to generate tool mabs for target validation.

Nikolai is a biochemist with 10+ years of industry experience in biotherapeutic discovery and optimization, primarily focused in oncology and autoimmunity therapeutic areas.

Nikolai Suslov
18:05– 19:05
Drinks-Canape Reception


Antibody Therapeutics Xchange | Boston 2024